Terns Pharmaceuticals Inc (NASDAQ: TERN) on Monday, plunged -2.29% from the previous trading day, before settling in for the closing price of $7.41. Within the past 52 weeks, TERN’s price has moved between $3.26 and $11.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. The company achieved an average annual earnings per share of -1.36%. With a float of $63.36 million, this company’s outstanding shares have now reached $64.58 million.
Let’s determine the extent of company efficiency that accounts for 66 employees. In terms of profitability, gross margin is 30.56%, operating margin of -8186.46%, and the pretax margin is -7233.74%.
Terns Pharmaceuticals Inc (TERN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Terns Pharmaceuticals Inc is 24.96%, while institutional ownership is 59.59%. The most recent insider transaction that took place on Sep 12 ’24, was worth 4,999,995. In this transaction Director of this company bought 476,190 shares at a rate of $10.50, taking the stock ownership to the 476,190 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Chief Financial Officer sold 10,000 for $11.00, making the entire transaction worth $110,000. This insider now owns 91,940 shares in total.
Terns Pharmaceuticals Inc (TERN) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.42 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.31) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.36% per share during the next fiscal year.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Terns Pharmaceuticals Inc (TERN) is currently performing well based on its current performance indicators. A quick ratio of 21.02 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Looking closely at Terns Pharmaceuticals Inc (NASDAQ: TERN), its last 5-days average volume was 0.97 million, which is a drop from its year-to-date volume of 1.28 million. As of the previous 9 days, the stock’s Stochastic %D was 15.42%. Additionally, its Average True Range was 0.51.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 26.82%, which indicates a significant increase from 3.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.59% in the past 14 days, which was lower than the 89.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.24, while its 200-day Moving Average is $7.02. However, in the short run, Terns Pharmaceuticals Inc’s stock first resistance to watch stands at $7.41. Second resistance stands at $7.58. The third major resistance level sits at $7.69. If the price goes on to break the first support level at $7.13, it is likely to go to the next support level at $7.02. Now, if the price goes above the second support level, the third support stands at $6.85.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
Market capitalization of the company is 611.35 million based on 64,677K outstanding shares. Right now, sales total 0 K and income totals -90,210 K. The company made 0 K in profit during its latest quarter, and -22,740 K in sales during its previous quarter.
